MAZE THERAPEUTICS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
MAZE THERAPEUTICS, INC. (MAZE) reported Increase (Decrease) in Prepaid Expense and Other Assets of $1.54 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- MAZE THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $1.94M, a 52.04% increase year-over-year.
- MAZE THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$404.00K, a 185.23% decline year-over-year.
- MAZE THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $433.00K, a 15.10% decline year-over-year.
- MAZE THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $758.00K, a 4953.33% increase year-over-year.
- MAZE THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $2.94M.
- MAZE THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$93.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.54M 10-Q · filed 2026-08-11 | $1.97M derived: sum of 3 quarters · filed 2026-08-11 | $2.73M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$404.00K 10-Q · filed 2026-05-12 | $29.00K derived: sum of 2 quarters · filed 2026-05-12 | $787.00K derived: sum of 3 quarters · filed 2026-05-12 | $2.06M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $433.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $1.19M derived: sum of 2 quarters · filed 2026-03-25 | $2.47M derived: sum of 3 quarters · filed 2026-08-11 | $2.94M 10-K · filed 2026-03-25 |
| 2025-09-30 | $758.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.03M derived: sum of 2 quarters · filed 2026-08-11 | $2.51M 10-Q · filed 2025-11-06 | $3.02M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.75M 10-Q · filed 2026-08-11 | $2.26M derived: sum of 3 quarters · filed 2026-08-11 | $2.27M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $474.00K 10-Q · filed 2026-05-12 | $984.00K derived: sum of 2 quarters · filed 2026-05-12 | $999.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.50M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $510.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $525.00K derived: sum of 2 quarters · filed 2026-03-25 | $1.02M derived: sum of 3 quarters · filed 2026-03-25 | -$93.00K 10-K · filed 2026-03-25 |
| 2024-09-30 | $15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $511.00K derived: sum of 2 quarters · filed 2025-11-06 | -$603.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $496.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$618.00K 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | -$1.11M 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |